An open label study to determine the effect on fasting glucose levels, and safety, of increasing doses of GK [glucokinase] activator(2) [RO 4389620] in patients with type 2 diabetes not optimally controlled with one previous oral antihyperglycemic agent
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2016
At a glance
- Drugs Piragliatin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 23 Feb 2010 Actual initiation date (Jul 2006) added from Roche record.
- 18 Jun 2007 Status changed from in progress to completed.